Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-013-6 | CAS number: 102110-15-6 A complex combination of hydrocarbons obtained by distillation of the products from a steam-cracking process. It consists predominantly of hydrocarbons having carbon numbers of C5 and dicyclopentadiene and boiling in the range of approximately 30°C to 170°C (86°F to 338°F).
An 18% and 14% decrease in terminal body weight was observed for the high dose males and females, respectively, as compared with their initial body weights. The terminal body weight loss for the high dose groups, as compared with the controls, was 18% for males and 13% for females. Both observed body weight reductions are considered test substance-related signs of systemic toxicity. The body weight loss in males is also considered biologically significant.
No statistically significant or biologically relevant effects on micronuclei frequencies were observed in the bone marrow cells in any dose group treated with DCPD/Codimer Concentrate. Although not statistically significant, a depression of approximately 30% in the PCE/NCE ratio was seen at 1750 mg/kg in females and demonstrates exposure of target cells to the test substance.
The vehicle and positive control groups exhibited a response consistent with the laboratory’s historical control data. The positive control, cyclophosphamide, induced a significant increase in the frequency of micronucleated PCEs (p < 0.05).
DCPD/Codimer Concentrate was evaluated for its ability to induce micronuclei in bone marrow polychromatic erythrocytes (PCEs) in male and female mice using groups of 5-7 mice/sex. Animals received 2 doses at 24 hour intervals and were assessed 24 hours after the second dose.
DCPD/Codimer Concentrate did not induce a statistically significant increase in micronucleated polychromatic erythrocytes in male or female mouse bone marrow. The highest dose administered on the study (1750 mg/kg body weight) gave clear evidence of clinical signs (both sexes) and exposure of the bone marrow to the substance (decreased PCE/NCE ratio) in females.
Based on these findings, DCPD/Codimer Concentrate (CAS 68478-10-4) was considered negative in this in vivo assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again